Marshall Wace North America’s Urovant Sciences Ltd. UROV Stock Holding History

Marshall Wace North America’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-47,523	Closed	-$766K	–	1916
2020 Q4	$766K	Buy	47,523 +4,977	+12%	+$61.7K	﹤0.01%	999
2020 Q3	$397K	Buy	42,546 +27,001	+174%	+$240K	﹤0.01%	1015
2020 Q2	$153K	Hold	15,545	–	–	﹤0.01%	1087
2020 Q1	$143K	Buy	+15,545	New	+$187K	﹤0.01%	950
2019 Q4	–	Sell	-2,567	Closed	-$24K	–	1735
2019 Q3	$24K	Buy	+2,567	New	+$22.3K	﹤0.01%	1222
2019 Q2	–	Sell	-4,902	Closed	-$49K	–	1809
2019 Q1	$49K	Buy	+4,902	New	+$50.3K	﹤0.01%	1267

Marshall Wace North America's UROV Position: Q1 2021 in Review

Marshall Wace North America sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 47,523 shares — an estimated $766K sold.

Marshall Wace North America first reported a position in UROV in Q1 2019 and held it in 6 quarters. The position peaked at $766K in Q4 2020. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Marshall Wace North America reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Marshall Wace North America sold 47,523 Urovant Sciences Ltd. shares in Q1 2021, an estimated $766K.
Marshall Wace North America first reported a position in Urovant Sciences Ltd. in Q1 2019 and held it in 6 quarters.
Marshall Wace North America's Urovant Sciences Ltd. position peaked at $766K in Q4 2020.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.